Trevi Therapeutics Schedules Q1 2026 Earnings Call for Haduvio Chronic Cough Treatment Updates
Trevi Therapeutics will report Q1 2026 financial results and provide corporate updates on Haduvio development for chronic cough treatment on May 5, 2026.
Intelligence Snapshot
Executive Summary
Trevi Therapeutics will host Q1 2026 earnings call and corporate update on May 5, 2026
Key Insights
-
Company developing Haduvio (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD,…
Company developing Haduvio (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and refractory chronic cough patients
-
Investors and stakeholders will receive updates on clinical progress and financial…
Investors and stakeholders will receive updates on clinical progress and financial performance
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | low |
| Investment | low |
Executive Scorecard
Heuristic scores · directional, not investment adviceContents7 sections
Key Takeaways
- Trevi Therapeutics will host Q1 2026 earnings call and corporate update on May 5, 2026
- Company developing Haduvio (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and refractory chronic cough patients
- Investors and stakeholders will receive updates on clinical progress and financial performance
NEW HAVEN, Conn. - Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced it will report first quarter 2026 financial results and provide a corporate update during a conference call and live audio webcast on Tuesday, May 5, 2026, at 4:00 PM ET.
About Haduvio Development Program
Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER), an investigational therapy targeting chronic cough in multiple patient populations. The company’s primary focus areas include:
- Idiopathic Pulmonary Fibrosis (IPF): A progressive lung disease affecting approximately 100,000-200,000 Americans
- Non-IPF Interstitial Lung Disease (non-IPF ILD): A group of lung conditions causing inflammation and scarring
- Refractory Chronic Cough (RCC): Persistent cough that doesn’t respond to standard treatments
IntelligenceRegulatory Impact
FDA set GMP, data-integrity, and post-approval change expectations for sterile and biologics manufacturing in the Americas. Regulatory relevance reads medium for pharmaceutical intelligence. Track inspection trends, Annex 1 alignment, and submission pathways for continuous manufacturing.
Market Opportunity and Clinical Significance
Chronic cough represents a significant unmet medical need, particularly in patients with underlying lung diseases. Current treatment options remain limited, creating substantial market opportunities for effective therapies like Haduvio.
The oral nalbuphine extended-release formulation offers potential advantages over existing treatments by targeting specific cough pathways while maintaining patient convenience through oral administration.
IntelligenceCompetitive Intelligence
Competitive pressure is low on capacity and tech-transfer positioning. Benchmark which CDMOs, equipment vendors, and sponsors adopt continuous and isolator platforms first. Supplier hub and pipeline links below connect to named partners.
What to Expect from the Call
The May 5th conference call will likely provide updates on:
- Clinical trial progress and patient enrollment status
- Regulatory interactions and potential pathway discussions
- Financial performance and cash runway
- Strategic partnerships or business development activities
IntelligenceMarket Signals
Commercial pull is medium for manufacturing capacity, outsourcing, and supply resilience. Investment relevance is low — watch capex, licensing, and regional hub expansion.
Investment Implications
For investors tracking respiratory medicine developments, this earnings call represents an important checkpoint for assessing Trevi’s progress in the competitive chronic cough treatment landscape. The company’s focus on multiple indications could provide diversified development opportunities and reduce clinical risk.
Stakeholders will be particularly interested in any updates regarding clinical milestones, regulatory feedback, or potential commercialization timelines for Haduvio across its target indications.
Frequently Asked Questions
What conditions does Haduvio treat?
Haduvio is being developed to treat chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough that doesn’t respond to standard treatments.
When will Haduvio be available to patients?
Haduvio is still in clinical development. The May 5, 2026 earnings call may provide updates on clinical trial progress and potential timelines, but the drug is not yet approved for commercial use.
How does Haduvio differ from existing cough treatments?
Haduvio uses oral nalbuphine extended-release formulation, which targets specific cough pathways and offers convenient oral administration. This approach may provide advantages over current limited treatment options for chronic cough conditions.
Related coverage
Ask AI About This Topic
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Stay Updated on Pharma News
Get the latest drug approvals, clinical trials, and regulatory updates delivered to your inbox.
- Evidence strength
- 71/100
- Last verified
- Jun 16, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Moderate source quality · grounded in cited primary and secondary sources.
This article follows our editorial standards. Report a correction via editorial contact.
